The study of prevalence of hyperuricemia and metabolic syndrome in type 2 diabetes mellitus

Sanjay A. Mundhe, Dinkar R. Mhasde


Background: Type 2 diabetes mellitus (Type 2 DM) is associated with cardiovascular complications, of which metabolic syndrome plays a prominent role. The metabolic syndrome is a cluster of cardiovascular risk factors characterized by central obesity, insulin resistance, dyslipidemia and hypertension. Hyperuricemia is gaining importance as cardiovascular risk factor and has role in renal and metabolic diseases. Our study was aimed to find out the prevalence of hyperuricemia and metabolic syndrome in type 2 DM and to evaluate association of hyperuricemia with metabolic syndrome.

Methods: This observational longitudinal study was carried out on 150 patients of type 2 DM patients for determination of hyperuricemia and components of metabolic syndrome.

Results: Metabolic syndrome was diagnosed in 68 patients (45.3%) with higher prevalence in males (53.4%) than females (33.9%). Hyperuricemia was found in 38 patients (25.3%) with higher prevalence in males (33%) than females (14.5%). Hyperuricemia and metabolic syndrome was found in 32 (21.3%) patients with higher prevalence among males (27.3%) than females (12.9%). The patients with hyperuricemia and metabolic syndrome compared to those without hyperuricemia and metabolic syndrome had higher mean age (63.16 versus 55), mean FBS (139.31 versus 117.23), mean duration of diabetes (12.66 versus 5.64), mean BMI (28.71 versus 24.61), systolic BP (128.50 versus 122.12), diastolic BP (80.63 versus 74.27), TG (176.28 versus 141.69) and lower HDL (39.63 versus 52.03).

Conclusions: Prevalence of hyperuricemia is higher in patients of type 2 diabetes with metabolic syndrome and is positively correlated with BMI, blood pressure and triglycerides and negatively correlated with HDL-C.


Atherogenic dyslipidemia, Cardiovascular risk, Central obesity, Hypertension, Hyperuricemia, Metabolic syndrome, Type 2 diabetes mellitus

Full Text:



Dedwania PC, Gupta R. Management issues in metabolic syndrome. J Assoc Physicians India. 2006;54:797-810.

Klein R, Klein BE, Cornoni J, Maready J, Cassel JC, Tyroler HA. Serum uric acid, Georgia .Arch Intern Med. 1973;132:401-10.

Bengtsson C, Lappidus L, Stendahal C, Waldenstrom J. Hyperuricemia and risk of cardiovascular disease and over all death. Acta Med Scand. 2002;224:549-55.

Nakagawa T, Cirillo P, Sato W, Gersch M, Sautin Y, Roncal C. The conundrum of hyperuricemia, metabolic syndrome and renal disease. Intern Emerg Med. 2008;3(4):313-8.

Cai Z, Xu X, Wu X, Zhou C, Li D. Hyperuricemia and Metabolic Syndrome. Asia Pac J Clin Nutr. 2009;18(1):81-7.

Chen LY, Jhu WH, Chen ZW, Di HL, Reh JJ. Relationship between hyperuricemia and metabolic syndrome. J Zhejiang Univ Sci B. 2007;8(8):593-8.

Reihmann M, Schutte A, Malan L, Huismann H, and Malan N. Hyperuricemia is an independent factor for metabolic syndrome in a sub- Saharan African population: A factor analysis. Atherosclerosis. 2008;197(2):638-45.

Palmer IM, Schutte AE, Huismann HW, Van Rooyen JM, Schutte R, Malan L. A comparison of uric acid levels in black Africans vs. Caucasian women from south Africa. The POWIRS study. Ethnicity and disease. 2007;17:670-6.

Alberti KG, Zimmet P, Shaw J. Metabolic syndrome- a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469-80.

Chizynki K, Rozycka M. Hyperuricemia. Pol Merkur Lekarski (in Polish). 2005;19(113):693-6.

Executive summary of third report of NCEP expert panel on detection, evaluation and treatment of high cholesterol in adults. [Expert panel]. JAMA. 2001;285:2486-97.

Ranmachandran A, Snehalatha G, Satyavathi K. Metabolic syndrome – in Urban Asian Indian Adults – A Population study using Modified ATP III criteria. Diab Res and clin Prac. 2003(60):199-203.

Misra A, Wasir JA, Pandey RM. Evaluation of candidate definitions of metabolic syndrome in adult Asian Indians. Diabetes Care. 2005;28(2):398-403.

Eliaseson B, Cederholm J, Nilsson P. The gap between guidelines and reality. Type 2 diabetes in a national diabetes register 1996 – 2003. Diabet Med. 2005;22(10):1420-6.

Vidal MP, Mazoyer P, Bougarl V. Prevalence of Insulin Resistance syndrome in South Western France and its relationship with inflammatory markers. Diabetes Care. 2002;25(8):1371-7.

Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am. J. Physiol. Renal Physiol. 2006;290(3):625-31.

Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F, et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health. 2004;4(1):9.

Schachter M. Uric acid and hypertension. Curr Pharm Des. 2004;11(32):4139-43.

Anthonia O, Alfred O. Hyperuricemia and metabolic syndrome in type 2 DM. Diabetol Metab Syndr. 2010;2:24.

Sumino H, Ichikawa S, Kanda T, Nakamura T, Sakamaki T. Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricemia. Lancet. 1999;354(9179):650.

Tuomilehto J, Wolf E, Talyor R, Ram P, King H. Plasma uric acid levels and its association with diabetes mellitus and some biologic parameters in biracial population of Fiji. American journal of epidemiology. 1988;127(2):321-36.

Tai ES, Emmanuel SC, Chew SK, Tan BY, Tan CE. Isolated low HDL cholesterol: an insulin-resistant state only in the presence of fasting hypertriglyceridemia. Diabetes. 1999;48(5):1088-92.

Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G. Low HDL cholesterol: a component of the metabolic syndrome only in the presence of fasting hypertriglyceridemia in type 2 diabetic patients. Diabetes Metab. 2001;27(1):31-5.

Bosello O, Zamboni M. Visceral obesity and metabolic syndrome. Obes Rev. 2000;1(1):47-56.

Rho YH, Choi SJ, Lee YH, Ji JD, Choi KM, Baik SH, et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci. 2005;20(6):1029-33.

Schmidt MI, Watson RL, Duncan BB, Metcalf P, Brancati FL, Sharrett R, et al. Clustering of dyslipidemia, hyperuricemia, diabetes and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators. Metabolism. 1996;45(6):699-706.

Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J. 2005;69(8):928-33.

Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003;42(3):247-52.